RE:Ceapro: Bright Outlook with Growth & Positive OCF for 2021Add also the fact that Ceapro will maintain a healthy balance sheet in 2021, based on the CEO's statements below.
stockfy wrote: The day traders will always whine because they want quick profits. The short-sighted inexperienced investors will always whine because they can't see the forest for the trees. However, these are the facts based on Ceapro's 2020 annual report:
- The YoY improvement both on the top line and the bottom line is huge.
- The YoY improvement on operating cash flow is huge too.
- The YoY improvement on the debt front is obvious too, because Ceapro is debt free now.
- Ceapro's current Enterprise Value is less than 10 times its adj. EBITDA, which is undeniably low.
- Continued progress on Oat beta glucan and cholesterol.
- Continued progress on Yeast beta glucan and COVID-19.
- Expansion into the marijuana sector and the chemical sector.
- Bright outlook for 2021 with growth and positive operating cash flow, facts below:
“I strongly believe 2021 holds a lot of opportunity for Ceapro. Our focus remains on the health and safety of our associates during this COVID-19 pandemic crisis, followed by business continuity. Depending on the evolution of the COVID-19 pandemic, we expect Ceapro’s cosmeceuticals base business to continue to grow and provide positive operating cash flows to support the expansion to a new business model from a contract manufacturer to a biopharmaceutical development company involved in nutraceuticals and pharmaceuticals. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.
The link:
https://www.globenewswire.com/news-release/2021/04/22/2215194/0/en/Ceapro-Inc-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Operational-Highlights.html